共 50 条
- [31] Glycemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study[J]. DIABETES, 2006, 55 : A114 - A115Halter, Jeffrey B.Kennedy, LaurenceHerman, William H.Miller, Michael E.
- [32] Glycaemic control and safety of insulin glargine (GLAR) in elderly patients with type 2 diabetes mellitus (T2DM): The GOAL A1C study[J]. DIABETOLOGIA, 2006, 49 : 602 - 603Halter, J.Kennedy, L.Miller, M.Herman, W.
- [33] NETWORK META-ANALYSIS (NMA) TO ASSESS RELATIVE EFFICACY MEASURED AS PERCENTAGE OF PATIENTS TREATED TO HBA1C TARGET WITH CANAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON METFORMIN AND SULPHONYLUREA (MET plus SU)[J]. VALUE IN HEALTH, 2015, 18 (07) : A598 - A598Taieb, VPacou, M.Schroeder, M.Schubert, A.Nielsen, A. T.
- [34] Insulin degludec/liraglutide (IDegLira) improves patient-reported outcomes in subjects with Type 2 diabetes inadequately controlled on insulin glargine (IGlar) plus metformin: DUAL V study[J]. DIABETIC MEDICINE, 2016, 33 : 65 - 65Viljoen, A.Brod, M.Perez Manghi, F. C.Garcia-Hernandez, P. A.Norwood, P.Jarlov, H.Kongso, J. H.Lingvay, I.
- [35] Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy[J]. DIABETES OBESITY & METABOLISM, 2006, 8 (02): : 156 - 163Garber, AKlein, EBruce, SSankoh, SMohideen, P
- [36] Similar glycemic control is achieved after discontinuation of thiazolidinediones (TZDs) and metformin (MET) in patients initiating insulin glargine (GLAR) as add-on therapy for type 2 Diabetes (T2DM): The GOAL A1C study[J]. DIABETES, 2005, 54 : A140 - A140Herman, WHKennedy, LHarris, AStrange, P
- [37] THE ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND ACHIEVEMENT OF DISEASE MANAGEMENT GOALS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM)[J]. VALUE IN HEALTH, 2014, 17 (03) : A257 - A257Traina, S. B.Neslusan, C.Slee, A.
- [38] Insulin Glargine (GLAR) and NPH Insulin (NPH) in Real Life in Russia in Patients with Type 2 Diabetes (T2D)[J]. DIABETES, 2009, 58 : A530 - A530Shestakova, Marina V.Glinkina, Irina V.
- [39] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL[J]. VALUE IN HEALTH, 2015, 18 (07) : A864 - A864Pititto, L.Neslusan, C.Teschemaker, A. R.Johansen, P.Willis, M.Asano, E.Puig, A.
- [40] ESTIMATING THE LIFETIME HEALTH OUTCOMES OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS INADEQUATELY CONTROLLED ON METFORMIN PLUS SULPHONYLUREA RECEIVING EITHER CANAGLIFLOZIN OR SITAGLIPTIN USING THE UKPDS OUTCOMES MODEL V1.3[J]. VALUE IN HEALTH, 2014, 17 (07) : A558 - A558Nuhoho, S.Worbes-Cerezo, M.